Trillium Therapeutics Inc. (TRIL)

Oncology Corporate Profile

Stock Performance

4.6000
-0.0500

HQ Location

96 Skyway Avenue
Toronto, Ontario, Canada M9W 4Y9

Company Description

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system.

Website: http://trilliumtherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TTI-621 (SIRPaFc)CD47 inhibitorVarious cancer typesI

Source: http://trilliumtherapeutics.com

Recent News Headlines

7/27/2017 12:20 pm

7/27/2017 12:20 pm

7/27/2017 12:20 pm

7/27/2017 12:20 pm

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

7/5/2017 12:20 am

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/28/2017 12:20 pm

6/7/2017 12:20 am

6/7/2017 12:20 am

6/7/2017 12:20 am

6/7/2017 12:20 am

6/7/2017 12:20 am

6/1/2017 12:20 pm

5/31/2017 12:20 am

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

4/3/2017 11:00 am

[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following preclinical and clinical updates on its TTI-621 ...

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

3/29/2017 11:00 am

[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the ...

Trillium Reports Annual 2016 Financial and Operating Results

3/10/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...